Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 20/20 | 0.65 |
| ▸ | THRB | P10828 | 19/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449955 | 0.88 | THRA (0.63) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24450095 | 0.84 | THRA (0.70) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL25128067 | 0.79 | THRA (0.59) | THRATHRBCYP2C9CYP2C8 | |
| SCHEMBL2920565 | 0.79 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24450010 | 0.78 | THRA (0.58) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24450005 | 0.78 | THRA (0.53) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL2927895 | 0.78 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL29527366 | 0.78 | THRB (0.50) | THRATHRBCYP2C9CYP2C8 | |
| SCHEMBL29066246 | 0.78 | THRB (0.50) | THRATHRBCYP2C9CYP2C8 | |
| SCHEMBL24449322 | 0.77 | THRA (0.63) | THRATHRBCYP2C9CYP2C8UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | THRA 1/4885THRB 2/4885CYP2C9 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.